NASDAQ:VRTX • US92532F1003
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VERTEX PHARMACEUTICALS INC (VRTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-18 | Maxim Group | Upgrade | Hold -> Buy |
| 2026-03-11 | Truist Securities | Maintains | Buy -> Buy |
| 2026-03-10 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-03-10 | B of A Securities | Maintains | Buy -> Buy |
| 2026-03-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-03-10 | Citigroup | Maintains | Buy -> Buy |
| 2026-03-10 | Jefferies | Initiate | Buy |
| 2026-03-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-17 | Barclays | Maintains | Overweight -> Overweight |
| 2026-02-17 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2026-02-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-13 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2026-02-13 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2026-02-13 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-13 | Stifel | Maintains | Hold -> Hold |
| 2026-02-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-28 | Barclays | Upgrade | Equal-Weight -> Overweight |
| 2026-01-26 | UBS | Maintains | Buy -> Buy |
| 2026-01-23 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-01-22 | RBC Capital | Upgrade | Sector Perform -> Outperform |
| 2026-01-12 | Bernstein | Upgrade | Market Perform -> Outperform |
| 2026-01-06 | Wolfe Research | Upgrade | Peer Perform -> Outperform |
| 2025-12-29 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-12-10 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-05 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 9.869B 10.51% | 11.02B 11.66% | 12.001B 8.90% | 13.299B 10.81% | 14.663B 10.26% | 16.415B 11.95% | 18.097B 10.25% | 19.962B 10.31% | 21.175B 6.08% | 22.871B 8.01% | 24.789B 8.39% | |
| EBITDA YoY % growth | 4.54B -0.96% | 4.603B 1.37% | 4.895B 6.35% | 5.741B 17.28% | 6.786B 18.20% | 7.702B 13.50% | 8.341B 8.30% | 9.253B 10.93% | 10.116B 9.33% | 10.802B 6.78% | 12.433B 15.10% | |
| EBIT YoY % growth | 4.359B -1.73% | 4.396B 0.84% | 4.685B 6.59% | 5.618B 19.91% | 6.522B 16.09% | 7.526B 15.39% | 8.98B 19.32% | 10.258B 14.23% | 11.409B 11.22% | 12.603B 10.47% | 14.164B 12.39% | |
| Operating Margin | 44.17% | 39.89% | 39.04% | 42.24% | 44.48% | 45.85% | 49.62% | 51.39% | 53.88% | 55.10% | 57.14% | |
| EPS YoY % growth | 15.22 2.22% | 0.29 -98.09% | 18.41 6,248.28% | 19.39 5.30% | 22.05 13.72% | 24.62 11.67% | 29.24 18.79% | 32.97 12.74% | 37.19 12.81% | 41.27 10.96% | 47.06 14.04% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 4.53 11.46% | 4.81 6.38% | 5.16 7.57% | 5.24 4.12% |
| Revenue Q2Q % growth | 3.127B 12.88% | 3.282B 10.70% | 3.335B 8.41% | 3.389B 6.24% |
| EBITDA Q2Q % growth | 1.357B 25.96% | 1.443B 15.13% | 1.544B 10.70% | 1.491B 1.28% |
| EBIT Q2Q % growth | 1.276B 24.02% | 1.374B 19.14% | 968.29M -21.96% | 1.473B 16.68% |
All data in USD
39 analysts have analysed VRTX and the average price target is 540.92 USD. This implies a price increase of 19.21% is expected in the next year compared to the current price of 453.74.
VERTEX PHARMACEUTICALS INC (VRTX) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of VERTEX PHARMACEUTICALS INC (VRTX) is 4.53 USD and the consensus revenue estimate is 3.13B USD.
The number of analysts covering VERTEX PHARMACEUTICALS INC (VRTX) is 39.